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Abstract
Background: The landscape of Human Immunodeficiency Virus (HIV) research has changed drastically over the past
three decades. With the remarkable success of antiretroviral treatment (ART) in decreasing AIDS-related mortality, some
researchers have shifted their HIV research focus from treatment to cure research. The HIV cure research community
often uses the term eradication to describe the science, and talks about eradicating the virus from the body. In public
discourse, the term eradication could be conflated with disease eradication at the population level. In this paper, we
call for a reframing of HIV cure research as control, as it is a more accurate descriptor and achievable goal in the
foreseeable future.
Discussion: The properties of HIV are discordant with eradicability standards at both the individual level (as a clinical
concept), and at the population level (as a public health concept). At the individual level, true eradication would
necessitate absolute elimination of all latent HIV reservoirs from the body. Current HIV cure-related research strategies
have proven unsuccessful at accurately quantifying, let alone eliminating these reservoirs. At the population level,
eradication implies the permanent global reduction of HIV to zero new cases and to zero risk for future cases. Given the
absence of an efficacious HIV vaccine and the impracticality and unethicality of eliminating animal reservoirs, global
eradication of HIV is highly implausible. From a public health perspective, HIV eradication remains an elusive goal.
Conclusion: The term ‘eradication’ is a misleading description of current HIV cure-related research. Instead, we call for
the use of more realistic expressions such as ‘sustained virologic HIV suppression (or control)’ or ‘management of HIV
persistence’ to describe HIV cure-related research. Using these terms reorients what HIV cure science can potentially
achieve in the near future and avoids creating unrealistic expectations, particularly among the millions of people
globally who live with HIV.
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Background
An estimated 36.7 (30.8–42.9) million people live with
HIV worldwide, and approximately 1.8 (1.6–2.1) million
new infections occurred in 2016 [1]. Global scale-up of
HIV antiretroviral treatment (ART) increased the life ex-
pectancy of people living with HIV, contributing to a 48%
reduction in AIDS-related mortality between 2005 and
2016 [1, 2]. However, ART does not remove replicative
HIV from the body and is not a cure [3]. Barriers to an
HIV cure include the persistence of quiescent HIV reser-
voirs that are not sensitive to or reached by ART nor vis-
ible to the immune system. The last decade has seen an
increase in biomedical HIV cure research [4]. The U.S.
Food and Drug Administration (FDA) defines HIV cure
research as: “any investigation that evaluates: 1) a thera-
peutic intervention or approach that controls or elimi-
nates HIV infection to the point that no further medical
interventions are needed to maintain health; and 2) pre-
liminary scientific concepts that might ultimately lead to
such a therapeutic intervention” [5]. HIV cure research in-
volves a variety of biomedical approaches (e.g. latency-
reversing compounds; early and intensified HIV therapy;
immune-based strategies and therapeutic vaccines; gene
editing; stem cell transplants; or combined approaches)
[4]. Two main pathways to achieving sustained ART-free
HIV suppression are under investigation: 1) removal of all
replication-competent HIV reservoirs from the body (clas-
sic biomedical cure), and 2) control of viral rebound in
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the absence of ART without complete elimination of HIV
(‘functional cure’) [6].
Eradication is a distinct concept at the individual level
and at the population level. On an individual patient
level, HIV cure would mean eradication of the virus
from the body. HIV cure remains an aspirational goal for
most people living with HIV. One person, Timothy Ray
Brown, has been cured of HIV infection [7], but the sci-
ence of HIV cure research has not progressed to the
point where eradication of HIV reservoirs from the body
(a cure) is possible. The primary intent of most HIV cure
interventions remains long-term virologic suppression of
HIV in the absence of ART. Most HIV cure research ap-
proaches under clinical investigation only have the cap-
acity to reduce but not eliminate the reservoir size or
augment the immune system’s ability to control HIV
while off ART. On a population level and as a public
health concept, eradication is defined as the permanent
reduction to zero of the worldwide incidence of a disease
[8]. For example, this would mean the elimination of
transmission and disease, as seen with smallpox eradica-
tion. From a public health perspective, eradication is in-
herently an incidence concept, not a cure concept.
Moreover, HIV does not meet the criteria for disease
eradicability set forth by the World Health Organization
(WHO) and the International Task Force for Disease
Eradication (ITFDE) [8, 9].
While the HIV cure research community uses the term
eradication as a clinical concept, it could easily be misin-
terpreted as disease eradication at a population level in
public discourse. Scientific groups such as the Collabora-
tive HIV Eradication of Viral Reservoirs (CHERUB), the
amfAR Research Consortium on HIV Eradication
(ARCHE) and the Collaboratory of AIDS Researchers for
Eradication (CARE) are dedicated to finding a clinical
cure for HIV infection. The biomedical HIV cure re-
search literature is also rich with examples of potential
‘eradication therapies’ for HIV infection [10–15]. The
term eradication is used to galvanize interest and fund-
ing in the science. Elimination would be a better term to
describe the complete disappearance of HIV from the
body as an aspirational cure goal. Instead of eradication,
we also suggest the use of expressions such as ‘long-term
virologic suppression (or control) off therapy’, or ‘man-
agement of HIV persistence’ [6, 16]. Control of HIV
makes much more sense as it is a well-documented con-
cept and can be linked appropriately to viral replication
[17, 18]. From a public health perspective, when the
term eradication is used loosely, it can easily be con-
flated with HIV elimination or control on a global scale.
The public should be informed that HIV cure research
will not lead to disease eradication on a population level.
Using the term ‘control’ on a clinical and population
levels provides a reorientation of what HIV cure science
can potentially achieve in the foreseeable future and
avoids creating false hopes and expectations [19], par-
ticularly among the millions of people globally who live
with HIV.
Discussion
The term eradication borrows its origins from the Latin
word eradicat, meaning “torn up by the roots” [20]. In
HIV cure-related research, the term eradication is used
to denote the complete elimination of all replication-
competent forms of the virus (eradicating or sterilizing
cure) [10]. Relatedly, language used to describe the sci-
ence provides an opportunity to educate the community
and potential volunteers regarding what can be accom-
plished to avoid the overestimation of possible medical
benefits [19]. Careful examination of HIV cure-related
research terminology reveals the terms used are com-
plex, and oftentimes considered only in narrow biomed-
ical contexts in isolation from the social contexts of
disease [17, 18]. HIV cure-related research carries hopes
and misconceptions. Using language such as cure or
eradication risks creating public misapprehension about
incremental research developments [18]. This paper
builds on the literature interrogating the use of language
in HIV cure-related research [17, 18, 21, 22] and on a
rich history of questioning language used in the scien-
tific literature in relation to HIV (e.g. for example, gay-
related immune deficiency (GRID) was renamed ac-
quired immune deficiency virus (AIDS) in 1982).
At the individual (clinical) level, the expression HIV control
is more descriptive than HIV eradication
Anthony Fauci, Director of the National Institute of Al-
lergies and Infectious Diseases (NIAID), stated: “the
complete eradication or elimination of HIV from an
HIV-infected individual would be extremely difficult to
achieve. At worst, it would be impossible. At best, it
would be achievable in a very small subset of the HIV-
infected population” [6].
At the individual level, HIV control may be considered
a more descriptive endpoint than eradication. Complete
removal of all HIV remnants is an extremely high bar to
achieve [18]. The fundamental biology of integrated pro-
viral HIV deoxyribonucleic acid (DNA) makes it nearly
impossible to know if all inducible virus has been re-
moved [13]. Another obstacle to curing HIV is ongoing
viral replication, even in the presence of ART [13]. The
suspected mechanism of this residual ongoing replica-
tion is direct cell-to-cell transmission, in which HIV
passes from an infected cell to an adjoining uninfected
cell [13]. Low-level viral replication escapes the effect of
ART and contributes to the long-term persistence of
HIV [13].
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Timothy Ray Brown, the Berlin patient, is the only
person currently cured of HIV [7]. His cure involved a
set of circumstances that have yet to be replicated. Fol-
lowing a relapsed acute myeloid leukemia (AML), he re-
ceived two stem cell transplants from a donor
homozygous for the CCR5 delta32 deletion. His initial
case was described as ‘long-term control of HIV’ [23].
Mr. Brown remained without replication-competent
provirus for over 10 years. However, a recent study
found trace amounts of replication-incompetent HIV
nucleic acid in his body (researchers did not exclude the
possibility of false positive results) [24]. Even with the
complete elimination of replication-competent HIV, fi-
nite particles of HIV may persist in the body, excluding
true viral eradication.
Other case histories are similarly illustrative of the
complexity of the issue and the need for precise lan-
guage. Even small HIV reservoirs do not guarantee in-
fection control when off ART [25]. A recent case study
showed an adult treated during early (Fiebig stage I)
HIV infection with prolonged HIV suppression, followed
by viral rebound. In this study, HIV treatment in the
earliest stage of HIV infection resulted in a small num-
ber of latently infected cells but did not eliminate repli-
cative HIV reservoirs [26]. The Mississippi child
represents another unusual case of prolonged HIV sup-
pression with small HIV reservoirs [27]. The perinatally
infected infant tested positive at birth for HIV and im-
mediately received ART. Her therapy was interrupted
against medical advice when she was between 18 and
23 months old. The Mississippi child remained with
undetectable viremia for approximately 27 months,
until HIV was detected in her blood at 46 months of
age [27]. Because she started ART very early, it is pos-
sible that her HIV reservoir size was negligible; how-
ever, the return of HIV after a prolonged period of
quiescent virus is consistent with the HIV latency hy-
pothesis [13]. Moreover, two patients from Boston
underwent allogeneic bone marrow transplants to treat
lymphoma, resulting in a reduction of their replication-
competent HIV reservoir size [28]. After a prolonged
period of ART-free suppression, their virus also
rebounded [29].
The Mississippi child and the Boston patients are em-
blematic cases demonstating the limits of HIV reservoir
size estimations. Current assays to measure residual
replication-competent HIV are not sufficiently sensitive
to rule-out incomplete clearance of HIV from blood or
tissues [10, 13, 30]. While some HIV cure research mo-
dalities aim to reduce the size of the inducible HIV res-
ervoir (e.g., latency-reversing agents or stem cell
transplants), prolonged ART-free suppression would re-
quire a drastic decrease in the pool of latently infected
cells. These cells are extremely rare, with an average
frequency of about 1 cell per 106 resting CD4+ T cell
lymphocytes [31]. The current gold standard for measur-
ing these replication-competent HIV reservoirs is the
Quantitative Viral Outgrowth Assay (QVOA). Though
sensitive, the QVOA underestimates the size of the
latent reservoir because some of the proviruses are not
induced even after several rounds of viral outgrowth
activation [32]. In the Mississippi child and the Boston
patients, for example, virus inducibility from latent
reservoirs could not be detected during aviremic in-
tervals, yet subsequent viral rebounds showed the
presence of reproducible virus below the limit of detection
[10, 29, 33]. The QVOA could not measure all latent virus
in tissue sanctuaries [34] or other reservoirs (e.g., those in
the brain) [35]. Biomedical HIV cure researchers posit that
only one replication-competent HIV DNA strand is
needed for a total eruption of viral replication. Thus, the
terms “reservoir reduction” or “viral control” may be bet-
ter aligned with strategies aimed at depleting the HIV res-
ervoir while strengthening the immune system’s ability to
fight reawakening virus [35].
Much like cancer, proviral HIV is a residual disease,
and a cure is limited by the persistence of rare cells [36].
Replication-competent reservoirs can exist in blood or
tissue even when they cannot be measured. The axiom
‘absence of evidence is not evidence of absence’ is apt in
this case. Due to the limited ability to measure latent
HIV, any patient who controls HIV off treatment would
still require indefinite clinical follow-up to monitor HIV
reactivation [30, 37].
Moreover, most current HIV cure research strategies
do not lead to a substantial reduction in the size of the
HIV reservoir. For example, early ART initiation re-
stricts, but does not eliminate HIV reservoirs [38, 39].
Latency-reversing agents have not yet shown to cause a
notable reduction in the size of the replication-
competent HIV reservoirs in clinical studies [40, 41].
Immunotherapeutic approaches are being investigated to
facilitate viral clearance [42–44], but do not inherently
result in HIV reservoir eradication, but rather the more
rapid removal of reactivating cells. Scientists are also
studying gene modification strategies, particularly those
blocking HIV cell entry [45]. Genetically-edited cells can
be reinfused into patients but to date engrafted cells rep-
resent a minority of the cell population, and viral relapse
is common following ART interruption [45]. In turn,
stem cell transplants involve risky procedures, such as
ablative conditioning, and are only appropriate for a very
small portion of people living with HIV who have an
underlying disease indicating such an approach [6]. To
date, no HIV cure research strategy has been able to
overcome the challenge of eliminating proviral HIV la-
tency or conferring viral suppression off ART at an indi-
vidual level.
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HIV does not meet criteria for eradicability at the
population level
On a global scale, eradication is often conflated with dis-
ease control, which refers to the reduction of disease
burden to an acceptable level, without the expectation
that the disease would disappear forever [46].
The term eradication in relationship to disease gained
popularity at the beginning of the twentieth century, fol-
lowing the establishment of germ theory and the growth
of public health policy focused on designing counter-
measures (e.g, vaccines and antibiotics). In 1909, the
Rockefeller Foundation sponsored the Sanitary Commis-
sion for the Eradication of Hookworm Disease, followed
by a similar Yellow Fever Commission in 1915 [46].
After the Second World War, eradication was endorsed
by the newly created WHO, with eradication efforts
against malaria, smallpox, yaws, poliomyelitis and guinea
worm disease (dracunculiasis) [46]. Smallpox was the
first, and thus far only, disease to meet the true absolut-
ist goal of eradication (1980), following an intense and
deliberate worldwide effort to bring its incidence to zero
[46]. Smallpox eradication required an efficacious vac-
cine conferring lifelong immunity, no animal hosts or
intermediate vectors, and high symptomaticity so the
disease could be identified efficiently during eradication
efforts. Smallpox also had a high profile in public health
in the twentieth century, and there was tremendous pol-
itical will to bring its global incidence down to zero [46].
As demonstrated with smallpox, the meaning of the
word eradication in global public health is the permanent
reduction to zero new cases, and zero risk of cases [47] –
or incidence of infection caused by a pathogen [8, 47].
Control in this context means the reduction of disease in-
cidence, prevalence, and/or morbidity or mortality to an
acceptable level, with continuous measures to keep the in-
fection under control [8]. Elimination of infection means
the reduction to zero of the incidence of disease with con-
tinuous efforts to prevent re-establishment of transmis-
sion [8]. Disease extinction signifies that the pathogen no
longer exists in nature or in the laboratory [8]. By this def-
inition, no infection meets the extinction criteria since
stocks of smallpox virus remain in two laboratories in At-
lanta, GA, USA, and Moscow, Russia [8].
The International Task Force for Disease Eradication
(ITFDE) has established their own criteria for disease
eradication. Examining over 90 diseases, the ITFDE de-
termined that only six – dracunculiasis, poliomyelitis,
mumps, rubella, lymphatic filariasis, and cysticercosis –
were candidates for eradication with currently available
biomedical interventions [9]. WHO subsequently called
for the elimination of leprosy, onchocerciasis, and Cha-
gas diseases as significant public health problems [8].
The criteria met by these diseases include: (1) easily di-
agnosed; (2) effective interventions (e.g., vaccines) exist
to break the cycle of transmission; and (3) infection occurs
only in humans (i.e., no animal reservoirs). Selecting a dis-
ease candidate for eradication is not only a question of sci-
entific feasibility, but also a matter of sincere political
commitment and funding [8, 9, 46]. HIV eradication on a
global scale is extremely difficult, if not impossible, to
achieve in the absence of a highly efficacious vaccine [48]
and the permanent existence of simian reservoirs harbor-
ing immunodeficiency virus. It would be impractical to
eliminate animal reservoirs, short of exterminating all
non-human primates in the wild carrying potentially in-
fectious virus. This would not only be environmentally
unacceptable and unethical, but also at odds with princi-
ples of ‘one health’ and disease ecology [46]. Therefore,
doubts remain as to the eradicability potential of HIV/
AIDS in humans on a global scale.
A public health perspective to HIV control
Eradication as an absolute goal may rest on an over-
reliance on biomedical technologies that fail to account
for the complexity of transmission [46]. To reduce the
worldwide burden of HIV, it is critical to adopt public
health strategies that leverage both biomedical and social
interventions [49, 50]. A purely biomedical, therapeutic,
or curative approach to HIV control is reductionist, fail-
ing to account for the complexity of disease. In fact, an
effective response to HIV should be informed by a pre-
diction of where the next 1000 new infections are likely
to emerge, taking into account the deeper, and more in-
tractable social, economic, behavioral, structural, and
political determinants of HIV [51]. Disease control will
rest on keeping up the “momentum for effective, com-
plex, combination HIV prevention and treatment efforts
over the long term” [51]. Yet scale-up of voluntary med-
ical male circumcision remains a challenge in several Af-
rican countries [52]. Additionally, we are far from
reaching the 90–90-90 HIV treatment targets globally
that would faciliate achieving epidemic control through
reduced viral loads [53]. An over-emphasis on thera-
peutic and curative biomedical technologies may my-
opically create solutions that are inadequate and
misguided to control such a profoundly social disease
[49]. A cure for HIV would be a tremendous scientific
achievement, but would unlikely lead to HIV elimination
as the disease is entangled with many complex structural
determinants. Over-excitement in the HIV cure en-
deavor may eclipse the myriad socio-structural factors
that create vulnerability to HIV in the first place [22].
On a global level, it may be worth asking if HIV ‘eradi-
cation’ is a worthwhile endeavor, knowing that animal
reservoirs exist and that zoonotic leaps may lead to re-
current outbreaks in humans much like those seen with
Ebola [54]. While eradication has been a useful end goal
for smallpox, with HIV it may be an example of over-
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confidence in biomedical approaches. From a public
health perspective, it may be time to scale back the HIV
eradication endeavor to focus instead on HIV control.
Conclusion
In sum, we argued for replacing the word eradication in
HIV cure science as it exists. On an individual level,
complete elimination of replication-competent HIV is an
extremely high bar to achieve. While the term eradica-
tion is meant as a clinical concept by the HIV cure re-
search community, it could be conflated with disease
eradication at the population level in public discourse.
On a population level, HIV eradication is an elusive goal,
since HIV does not meet the criteria for disease eradic-
ability [8, 9]. Framing HIV cure research as control re-
search may help us calibrate expectations of what is
possible, at least in the short term [19]. Eradication re-
quires perfection, setting the bar high and engendering
chronic disappointment. Additionally, focusing on HIV
eradication could lead to premature abandonment of a
worthwhile enterprise. Further empirical research is
needed to determine how people living with HIV, and
other stakeholders, perceive the word eradication when
discussing HIV cure research. We advocate to use ex-
pressions such as ‘sustained virologic HIV suppression
(or control) off treatment’ [6] or ‘management of HIV
persistence’ [16] to describe HIV cure-related research.
These are more realistic and relevant endpoints. The
control paradigms at individual and population levels
allow us to more aptly appreciate incremental achieve-
ments in scientific research [19].
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